0001084577 false --12-31 00-0000000 0001084577 2022-02-07 2022-02-07 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of report (Date of earliest event reported): February 7, 2022

 

CYREN LTD.

(Exact Name of Registrant as Specified in its Charter)

 

Israel   000-26495   Not applicable
(State or Other Jurisdiction
of Incorporation) 		  (Commission File Number)   (IRS Employer
Identification No.)

 

10 Ha-Menofim St., 5th Floor
Herzliya, Israel 		  4672561
(Address of Principal Executive Offices)   (Zip Code)

 

011–972–9–863–6888

(Registrant’s telephone number, including area code)

 

  

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading symbol(s)   Name of exchange on which
registered
Ordinary Shares, par value ILS 3.00 per share   CYRN   Nasdaq Capital Market

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). 

 

☐ Emerging growth company

 

☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

 

 

 

 

 

 

Item 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year.

 

The information in Item 8.01 below regarding the amendment to the Articles of Association of Cyren Ltd., a company formed under the laws of the State of Israel (the “Company”) is incorporated by reference into this Item 5.03.

 

Item 5.07 Submission of Matters to a Vote of Security Holders.

 

On February 7, 2022, the Company held a Special Meeting of Shareholders (the “Special Meeting”). At the Special Meeting, the Company’s shareholders voted on the following proposals: (i) to approve an amendment to the Company's Amended and Restated Articles of Association (the “Articles of Association”) to effect a reverse share split of the Company's ordinary shares (the "Reverse Share Split") at a ratio of not less than one-for-four and not more than one-for-twenty, with such ratio and the implementation and timing of the Reverse Share Split to be determined by the Company's board of directors in its sole discretion within thirty days of the Special Meeting (“Proposal One”) and (ii) subject to the approval of Proposal One, to approve an increase in the authorized share capital by up to NIS 216,000,000 to 240,000,000 and amend the Company’s Articles of Association accordingly (“Proposal Two”). Each of the proposals is described in more detail in the proxy statement filed with the Securities and Exchange Commission on January 5, 2022. The results of the votes are set forth below.

 

Proposal One

 

The shareholders approved Proposal 1.

 

For     Against     Abstain     Broker Non-Vote  
  52,154,393       2,808,499       12,893       —  

 

Proposal Two

 

The shareholders, following the approval of Proposal One, approved Proposal 2.

 

For     Against     Abstain     Broker Non-Vote  
  51,418,517       3,524,039       33,229       —  

  

Item 8.01 Other Information.

 

Following the Special Meeting, on February 7, 2022, the board of directors of the Company approved a one-for-twenty Reverse Share Split and an increase in the Company’s authorized share capital by NIS 216,000,000, and the Articles of Association of the Company were amended accordingly. The Reverse Share Split became effective on February 9, 2022. Additionally, effective at the same time, the total number of ordinary shares the Company is authorized to issue after the effect of the Reverse Share Split is 80,000,000, the par value per ordinary share is NIS 3.00 and the authorized share capital of the Company is NIS 240,000,000.

 

Upon the effectiveness of the Reverse Share Split, every twenty ordinary shares were automatically combined and converted into one ordinary share. Appropriate adjustments were also made to all outstanding derivative securities of the Company, including all outstanding equity awards and warrants.

   

No fractional shares were issued in connection with the reverse share split. Instead, all fractional shares (including shares underlying outstanding equity awards and warrants) were rounded up to the nearest whole ordinary share.

 

1

 

 

The Company’s ordinary shares will continue to trade on The Nasdaq Stock Market LLC under the symbol “CYRN.” The new CUSIP number for the ordinary shares following the Reverse Share Split is M26895132.

 

On February 8, 2021, the Company issued a press release announcing the foregoing. The press release is attached hereto as Exhibit 99.1 and incorporated herein by reference.

 

The foregoing summary of the effect of the Articles of Association, as amended, is qualified in its entirety by reference to the full text thereof, which is attached hereto as Exhibit 3.2 and incorporated herein by reference.

 

Item 9.01 Financial Statement and Exhibits.

 

  (d) Exhibits.

 

Exhibit
Number 		  Exhibits
3.2   Amended and Restated Articles of Association of the Company, as amended on February 7, 2022.
     
99.1   Press release issued by Cyren Ltd. on February 8, 2022.
     
104.1   Cover Page Interactive Data File (embedded within the inline XBRL document).

 

2

 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  CYREN LTD.
Dated: February 9, 2022    
  By: /s/ Kenneth Tarpey
  Name:  Kenneth Tarpey
  Title: Chief Financial Officer

 

 

3

 

CYREN (NASDAQ:CYRN)
Historical Stock Chart
From Jun 2024 to Jul 2024 Click Here for more CYREN Charts.
CYREN (NASDAQ:CYRN)
Historical Stock Chart
From Jul 2023 to Jul 2024 Click Here for more CYREN Charts.